Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review

The Journal of Community and Supportive Oncology, 2016 01; 14(1): 21-28. e-pub ahead of print 2016/02/13

Cancer patients treated with epidermal growth factor receptor inhibitors (EGFRIs) frequently experience skin toxicities (rash) that can compromise their quality of life and lead to dose reduction or discontinuation of treatment. Reflecting the need for effective management of EGFRI-associated rash, a number of clinical practice guidelines and management recommendations have been developed. The objective of this systematic review is to identify and summarize all available published recommendations of rash management strategies and evaluate their basis of evidence, to describe consensus in the recommendations, and where there is a lack of consensus to describe the opportunities for future clinical research to improve clinical practice in the management of EGFRI rash.

View abstract


Brown J, Su Y, Nelleson D, Shankar P, Mayo C.